deltatrials
Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03917043

APG-2449 in Patients With Advanced Solid Tumors

A Phase I Study of the Safety, Pharmacokinetic and Pharmacodynamic Properties of Orally Administered APG-2449 in Patients With Advanced Solid Tumors

Sponsor: Ascentage Pharma Group Inc.

Conditions Advanced Solid Cancer Esophageal Cancer Malignant Pleural Mesothelioma Non Small Cell Lung Cancer Ovarian Cancer
Interventions APG-2449
Updated 18 times since 2019 Last updated: Jun 16, 2025 Started: May 27, 2019 Primary completion: Dec 31, 2027 Completion: Jan 31, 2028
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Advanced Solid Cancer and Esophageal Cancer and is currently actively recruiting participants. Ascentage Pharma Group Inc. leads this study, which shows 18 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~May 2019 – ~Jul 2019 · 2 months · monthly snapshot~Jul 2019 – ~Aug 2020 · 13 months · monthly snapshot~Aug 2020 – ~Nov 2020 · 3 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Dec 2021 · 2 months · monthly snapshot~Dec 2021 – ~May 2022 · 5 months · monthly snapshot~May 2022 – ~Sep 2022 · 4 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshot~Sep 2023 – ~Dec 2023 · 3 months · monthly snapshot~Dec 2023 – ~Jul 2024 · 7 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Mar 2025 · 3 months · monthly snapshot~Mar 2025 – ~May 2025 · 2 months · monthly snapshot~May 2025 – ~Jul 2025 · 2 months · monthly snapshot~Jul 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Jul 2025 — Present [monthly]

    Recruiting PHASE1

  2. May 2025 — Jul 2025 [monthly]

    Recruiting PHASE1

  3. Mar 2025 — May 2025 [monthly]

    Recruiting PHASE1

  4. Dec 2024 — Mar 2025 [monthly]

    Recruiting PHASE1

  5. Sep 2024 — Dec 2024 [monthly]

    Recruiting PHASE1

▶ Show 13 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE1

  2. Dec 2023 — Jul 2024 [monthly]

    Recruiting PHASE1

  3. Sep 2023 — Dec 2023 [monthly]

    Recruiting PHASE1

  4. Sep 2022 — Sep 2023 [monthly]

    Recruiting PHASE1

  5. May 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

  6. Dec 2021 — May 2022 [monthly]

    Recruiting PHASE1

  7. Oct 2021 — Dec 2021 [monthly]

    Recruiting PHASE1

  8. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  9. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  10. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  11. Aug 2020 — Nov 2020 [monthly]

    Recruiting PHASE1

  12. Jul 2019 — Aug 2020 [monthly]

    Recruiting PHASE1

    Status: Not Yet Recruiting → Recruiting

  13. May 2019 — Jul 2019 [monthly]

    Not Yet Recruiting PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Ascentage Pharma Group Inc.
  • Suzhou Yasheng Pharmaceutical Co., Ltd.
Data source: Ascentage Pharma Group Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations